PMID- 28265415
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2052-9538 (Print)
IS  - 2052-9538 (Electronic)
IS  - 2052-9538 (Linking)
VI  - 4
DP  - 2017
TI  - Metabolic improvements following Roux-en-Y surgery assessed by solid meal test in 
      subjects with short duration type 2 diabetes.
PG  - 10
LID - 10.1186/s40608-017-0149-1 [doi]
LID - 10
AB  - BACKGROUND: Glucose homeostasis improves within days following Roux-en-Y gastric 
      bypass (RYGB) surgery. The dynamic metabolic response to caloric intake following 
      RYGB has been assessed using liquid mixed meal tolerance tests (MMTT). Few 
      studies have evaluated the glycemic and hormonal response to a solid mixed meal 
      in subjects with diabetes prior to, and within the first month following RYGB. 
      METHODS: Seventeen women with type 2 diabetes of less than 5 years duration 
      participated. Fasting measures of glucose homeostasis, lipids and gut hormones 
      were obtained pre- and post-surgery. MMTT utilizing a solid 4 oz chocolate 
      pudding performed pre-, 2 and 4 weeks post-surgery. Metabolic response to 4 and 2 
      oz MMTT assessed in five diabetic subjects not undergoing surgery. RESULTS: 
      Significant reductions in fasting glucose and insulin at 3 days, and in fasting 
      betatrophin, triglycerides and total cholesterol at 2 weeks post-surgery. Hepatic 
      insulin clearance was greater at 3 days post-surgery. Subjects exhibited less 
      hunger and greater feelings of fullness and satisfaction during the MMTT while 
      consuming 52.9 +/- 6.5% and 51.0 +/- 6.5% of the meal at 2 and 4 weeks post-surgery 
      respectively. At 2 weeks post-surgery, glucose and insulin response to MMTT were 
      improved, with greater GLP-1 and PYY secretion. Improved response to solid MMTT 
      not replicated by consumption of smaller pudding volume in diabetic non-surgical 
      subjects. CONCLUSIONS: With a test meal of size and composition representative of 
      the routine diet of post-RYGB subjects, improved glycemic and gut hormone 
      responses occur which cannot be replicated by reducing the size of the MMTT in 
      diabetic subjects not undergoing surgery. TRIAL REGISTRATION: Clinical Trials.gov 
      Identifier: NCT00957957 August 11, 2009.
FAU - Shankar, Sudha S
AU  - Shankar SS
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Mixson, Lori A
AU  - Mixson LA
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Chakravarthy, Manu
AU  - Chakravarthy M
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Chisholm, Robin
AU  - Chisholm R
AD  - Division of Endocrinology, Department of Medicine, Indiana University School of 
      Medicine, Indianapolis, IN USA. ISNI: 0000 0001 2287 3919. GRID: grid.257413.6
FAU - Acton, Anthony J
AU  - Acton AJ
AD  - Division of Endocrinology, Department of Medicine, Indiana University School of 
      Medicine, Indianapolis, IN USA. ISNI: 0000 0001 2287 3919. GRID: grid.257413.6
FAU - Jones, RoseMarie
AU  - Jones R
AD  - Community Bariatric Services, Indianapolis, IN USA.
FAU - Mattar, Samer G
AU  - Mattar SG
AD  - Department of Surgery, Oregon Health & Science University, Portland, OR USA. 
      ISNI: 0000 0000 9758 5690. GRID: grid.5288.7
FAU - Miller, Deborah L
AU  - Miller DL
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Petry, Lea
AU  - Petry L
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Beals, Chan R
AU  - Beals CR
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Stoch, S Aubrey
AU  - Stoch SA
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Kelley, David E
AU  - Kelley DE
AD  - Experimental Medicine, Merck and Company, Rahway, NJ USA. ISNI: 0000 0001 2260 
      0793. GRID: grid.417993.1
FAU - Considine, Robert V
AU  - Considine RV
AD  - Division of Endocrinology, Department of Medicine, Indiana University School of 
      Medicine, Indianapolis, IN USA. ISNI: 0000 0001 2287 3919. GRID: grid.257413.6
LA  - eng
SI  - ClinicalTrials.gov/NCT00957957
GR  - P30 DK097512/DK/NIDDK NIH HHS/United States
PT  - Journal Article
DEP - 20170301
PL  - England
TA  - BMC Obes
JT  - BMC obesity
JID - 101639183
PMC - PMC5331732
OTO - NOTNLM
OT  - C-peptide
OT  - GLP-1
OT  - Glucose
OT  - Gut hormones
OT  - Insulin
OT  - Meal test
OT  - Roux-en-Y
EDAT- 2017/03/08 06:00
MHDA- 2017/03/08 06:01
PMCR- 2017/03/01
CRDT- 2017/03/08 06:00
PHST- 2016/11/01 00:00 [received]
PHST- 2017/02/14 00:00 [accepted]
PHST- 2017/03/08 06:00 [entrez]
PHST- 2017/03/08 06:00 [pubmed]
PHST- 2017/03/08 06:01 [medline]
PHST- 2017/03/01 00:00 [pmc-release]
AID - 149 [pii]
AID - 10.1186/s40608-017-0149-1 [doi]
PST - epublish
SO  - BMC Obes. 2017 Mar 1;4:10. doi: 10.1186/s40608-017-0149-1. eCollection 2017.